Heart-Valve-Surgery.Com and Medtronic Launch Novel "Aortic Stenosis Patient Activation Platform" to Empower Patients
Heart-Valve-Surgery.Com and Medtronic Launch Novel "Aortic Stenosis Patient Activation Platform" to Empower Patients
LOS ANGELES, April 25, 2024 /PRNewswire/ -- Heart-Valve-Surgery.com, a leading patient advocacy group for heart valve disease, with support from Medtronic, a global leader in healthcare technology, today launched the "Aortic Stenosis Patient Activation Platform", an end-to-end digital platform for patient awareness, patient education, and patient activation specific to aortic valve stenosis.
洛杉磯，2024年4月25日 /PRNewswire/ — 領先的心臟瓣膜疾病患者權益組織Heart-valve-Surgery.com在全球醫療保健技術領導者美敦力的支持下，今天推出了 “主動脈瓣狹窄患者激活平台”，這是一個針對主動脈瓣狹窄的患者意識、患者教育和患者激活的端到端數字平台。
Aortic stenosis is a narrowing of the aortic valve which prevents the aortic leaflets from opening and closing properly. As a result, the heart must work "over time" to pump blood throughout the body. Patients with aortic stenosis often have heart murmurs and experience debilitating symptoms including chest pain, dizziness, fatigue, shortness of breath and an irregular heartbeat.
主動脈瓣狹窄是主動脈瓣的變窄，它會阻止主動脈葉片正常打開和關閉。因此，心臟必須 “隨着時間的推移” 發揮作用，將血液泵送到全身。主動脈瓣狹窄患者經常有心臟雜音並出現使人衰弱的症狀，包括胸痛、頭暈、疲勞、呼吸急促和心跳不規律。
"Aortic stenosis is a deadly and under-treated disease," states Dr. Ashish Aneja, Director of Non-Invasive Cardiology at MetroHealth. Without treatment, up to 50% of patients will die 24 months after the onset of symptoms1. According to Dr. Kendra Grubb, Surgical Director of the Emory Structural Heart & Valve Center, approximately 40%† of patients with aortic stenosis in the United States do not get treatment because their symptoms are often misdiagnosed or ignored2.
MetroHealth非侵入性心臟病學董事阿什什·安內亞博士說：“主動脈瓣狹窄是一種致命且治療不足的疾病。”如果不進行治療，多達50％的患者將在症狀出現24個月後死亡1。根據埃默裏結構心臟和瓣膜中心外科主任肯德拉·格拉布博士的說法，在美國，大約40％†的主動脈瓣狹窄患者沒有得到治療，因爲他們的症狀經常被誤診或忽視2。
Two common approaches for treating aortic stenosis include surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR). During the past 10 years, there has been a significant increase in the use of TAVR for aortic stenosis as the estimated number of TAVR procedures performed per year in the United States has increased from 4,600 procedures in 2012 to over 100,000 procedures in 20233.
治療主動脈瓣狹窄的兩種常見方法包括手術主動脈瓣置換（SAVR）和經導管主動脈瓣置換（TAVR）。在過去的10年中，隨着美國每年進行的TAVR手術的估計數量已從2012年的4,600例增加到2023年的超過10萬例手術，TAVR治療主動脈瓣狹窄的使用顯著增加3。
Because treatment continues to increase and evolve, the "Aortic Stenosis Patient Activation Platform", developed by Heart-Valve-Surgery.com with support from Medtronic and a world-renowned team of physicians, will increase awareness and education for aortic stenosis patients. The proprietary platform leverages artificial intelligence, patient-centric algorithms, geolocation strategies, next-generation telephony engines, robust patient databases, and a social media following of over 500,000 people.
由於治療不斷增加和發展，Heart-valve-surgery.com在美敦力和世界知名醫生團隊的支持下開發的 “主動脈瓣狹窄患者激活平台” 將提高對主動脈瓣狹窄患者的認識和教育。該專有平台利用人工智能、以患者爲中心的算法、地理定位策略、下一代電話引擎、強大的患者數據庫以及超過500,000人的社交媒體。
"Using an integrated system of proprietary digital building blocks, the Aortic Stenosis Patient Activation Platform helps patients establish real-time connections with fifty heart teams that specialize in aortic stenosis treatment," states Adam Pick, who started Heart-Valve-Surgery.com after having an aortic valve replacement in 2006.
亞當·皮克說：“主動脈瓣狹窄患者激活平台使用由專有數字構件組成的集成系統，幫助患者與五十個專門從事主動脈瓣狹窄治療的心臟團隊建立實時聯繫，” 亞當·皮克說，他在2006年接受主動脈瓣置換術後創辦了Heart-valve-surgery.com。
"At Medtronic, we are committed to helping aortic stenosis patients benefit from durable, minimally invasive devices that consider the lifetime management of heart valve disease," stated Nina Goodheart, Senior Vice President and President, Structural Heart & Aortic, which is part of the Cardiovascular Portfolio at Medtronic. "We appreciate the opportunity to partner with Heart-Valve-Surgery.com and heart teams across the nation on this important initiative."
美敦力心血管產品組合下結構心臟與主動脈科高級副總裁兼總裁妮娜·古德哈特表示：“在美敦力，我們致力於幫助主動脈瓣狹窄患者受益於耐用的微創設備，這些設備考慮了心臟瓣膜疾病的終身管理。”“我們很高興有機會與Heart-valve-surgery.com和全國各地的心臟團隊合作開展這項重要計劃。”
To experience the Aortic Stenosis Patient Activation Platform, please click here.
要體驗主動脈瓣狹窄患者激活平台，請點擊此處。
To explore the TAVR Heart Team Finder, please click here.
要瀏覽 TAVR 心臟團隊查找器，請點擊此處。
To download the new eBook, "Medtronic TAVR Procedure: What 7 Facts Should Patients Know?", click here.
下載新的電子書《美敦力 TAVR 程序：患者應該知道哪七個事實？》，點擊這裏。
About Heart-Valve-Surgery.com
關於 Heart-valve-surgery.com
Founded in 2006, Heart-Valve-Surgery.com is the largest educational resource and community of patients with heart valve disease. This award-winning and HONcode certified website, which is sponsored by 40+ cardiac centers, has helped more than 10 million people manage and treat heart valve disease. Adam Pick, the patient advocate who started Heart-Valve-Surgery.com, is followed by 500,000 people across social media for his patient-centric coverage of heart valve disease.
Heart-valve-surgery.com成立於2006年，是最大的心臟瓣膜病患者教育資源和社區。這個屢獲殊榮並獲得HONcode認證的網站由40多個心臟中心贊助，已幫助超過1000萬人管理和治療心臟瓣膜疾病。創辦Heart-valve-surgery.com的患者權益倡導者亞當·皮克因其以患者爲中心的心臟瓣膜疾病報道而在社交媒體上受到50萬人關注。
References:
參考文獻：
† Reflects total number of patients who could receive an aortic valve replacement.
† 反映了可以接受主動脈瓣置換術的患者總數。
1 Ross J Jr, Braunwald E. Aortic stenosis. Circulation. July 1968;38(1 Suppl):61-67.
1 Ross J Jr，Braunwald E. 主動脈瓣狹窄。流通。1968 年 7 月；38（補編 1）：61-67。
2 Medtronic Data on File.
2 存檔的美敦力數據。
3 Society of Thoracic Surgeons National Database and Cardiovascular Business, Presented by Dr. Michael Mack at Controversies & Advances in the Treatment of Cardiovascular Disease Conference, December, 2023.
3 胸外科醫生協會國家數據庫和心血管業務，由邁克爾·麥克博士在2023年12月心血管疾病治療的爭議與進展會議上發表。
Media Contact:
Katie Bal
310-266-4525
媒體聯繫人：
凱蒂·巴爾
310-266-4525
SOURCE Heart-Valve-Surgery.com
來源 Heart-valve-surgery.com
譯文內容由第三人軟體翻譯。